- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...

WAYNE, Pa., April 13, 2021 /PRNewswire/ — Evolve IP (R), a leading international service provider of Work AnywhereTM solutions, today announced that Paradigm Technology Group, an IT services ...

Paradigm Learning, a designer of business games and simulations that help companies align employees around their vision and develop skills needed to execute that vision, has announced it will now ...

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...

Paradigm would like to report to its shareholders that there are currently 839,680,555 outstanding shares, unchanged from our last report. The company has made significant progress over the course of ...

Paradigm and Film2Future have inked a two-year collaborative agreement that will see the talent agency become the exclusive partner of the non-profit that promotes pathways into the entertainment ...

WASHINGTON, May 2, 2024 /PRNewswire/ -- The National Association of Investment Companies (NAIC) is pleased to announce the 2024 cohort of Paradigm Changers interns. Launched in 2021, NAIC's Paradigm ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...